Dynavax Technologies

454 articles with Dynavax Technologies

• Dynavax to Present at the H.C. Wainwright Global Investment Conference

  5/16/2022

  Dynavax Technologies Corporation announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022.

• Dynavax Reports First Quarter 2022 Financial Results

  5/5/2022

  Dynavax Technologies Corporation reported financial results and provided business updates for the three months ending March 31, 2022.

• 

  AstraZeneca Touts Evusheld's Efficacy in High-Risk Patients

  4/21/2022

  Clinical results announced this week could expand COVID-19 prevention options for the immunocompromised and vaccine ineligible, as well as those that have already contracted COVID.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 05, 2022

  4/5/2022

  Dynavax Technologies Corporation reported that it has granted restricted stock units covering an aggregate of 28,250 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 08, 2022

  3/8/2022

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 33,250 shares of Dynavax common stock and restricted stock units covering an aggregate of 48,250 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 03, 2022

  3/3/2022

  Dynavax Technologies Corporation reported that it has granted restricted stock units covering an aggregate of 16,000 shares of Dynavax common stock as inducements to 2 newly-hired employees in connection with commencement of employment with the Company.

• Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance

  2/28/2022

  Dynavax Technologies Corporation, a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, reported record 2021 total revenue of $439.4 million for the full year of 2021, marking a significant increase compared to $46.6 million for 2020.

• Dynavax to Present at the Cowen 42nd Annual Health Care Conference

  2/23/2022

  Dynavax Technologies Corporation announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 02, 2022

  2/2/2022

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 105,000 shares of Dynavax common stock and restricted stock units covering an aggregate of 73,250 shares of Dynavax common stock as inducements to 11 newly-hired employees in connection with commencement of employment with the Company.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2022

  1/7/2022

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units covering an aggregate of 2,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.

• Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

  1/5/2022

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing vaccines, announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022.

• Elaine D. Sun Appointed to Dynavax Board of Directors - Dec 14, 2021

  12/14/2021

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines to protect the world against infectious diseases, announced the appointment of Elaine Sun to its Board of Directors.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 02, 2021

  12/2/2021

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 58,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.

• Dynavax Reports Third Quarter 2021 Financial Results

  11/4/2021

   Dynavax Technologies Corporation  today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2021

  11/2/2021

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 5,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.

• Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman

  10/21/2021

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced the appointment of Scott Myers to its Board of Directors.

• Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021

  10/21/2021

  Dynavax Technologies Corporation will report third quarter 2021 financial results on Thursday, November 4, 2021, after the U.S. financial markets close.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 18, 2021

  10/18/2021

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 115,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.

• COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial

  10/18/2021

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing vaccines, announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018® adjuvant.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 40,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.